Drug price dialogues represent ‘an opportunity for CMS to clarify negotiation policies and their potential impact for the future’

CMS drug price negotiations

Photo by Andrea Piacquadio via Pexels

CMS must ensure transparency, clarity and predictability by providing detailed guidance on comparator drug selection and the evaluation of evidence, according to a group of D.C.-based health policy researchers.